DEF 14ASMMTCIK 0001599298

Summit Therapeutics Inc.

Name: SEC EDGAR filing 0001599298-26-000029
Creator: Summit Therapeutics Inc.
License: https://www.usa.gov/government-works

Proxy statement (DEF 14A) filed April 17, 2026.

Definitive proxy statement disclosing matters to be voted on by shareholders, including executive compensation.

Read the filing on SEC.gov All documents in this filing

New to the DEF 14A? What it is and how to read one

Filing facts

Accession number: 0001599298-26-000029
Filer: Summit Therapeutics Inc.
Ticker: SMMT
CIK: 0001599298
Form type: DEF 14A
Form description: Proxy statement
Filed at: April 17, 2026
Period of report: April 17, 2026
Industry: SIC 2834Pharmaceutical Preparations
Filing size: 3.3 MB
Last verified: August 26, 2026SecFilingDex pulls from EDGAR with daily cadence

More filings from Summit Therapeutics Inc.

See all 44 filings from Summit Therapeutics Inc. →

Provenance

Authoritative source — SEC EDGAR

https://www.sec.gov/Archives/edgar/data/1599298/000159929826000029/0001599298-26-000029-index.htm ↗

Filer's full EDGAR submission history

EDGAR · Summit Therapeutics Inc. (0001599298) ↗

SecFilingDex republishes SEC EDGAR data with provenance. EDGAR is the authoritative source. SecFilingDex is independent and not affiliated with the U.S. Securities and Exchange Commission. Nothing on this page constitutes investment, legal, tax, or other professional advice.